Age: 57.0
Sex: F
Vaccine: FLU3, VARZOS
Symptoms: Myalgia, Rash erythematous, Urticaria, Vaccination site reaction
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 19-May-2018 by Seqirus from VAERS (VAERS ID: 699746), concerns a 57-year-old, adult, female patient. The patient had no medical history, drug reactions, allergies and concomitant medications. On 13-May-2017, the patient received FLUVIRIN Thiomersal [dose: 0.5 ml (reported as 1st dose), route of administration: injection (reported as SYR), anatomical location: left arm, batch number: 1720801 and expiry date: not reported] and non-company suspect ZOSTAVAX (dose: 0.65 ml, route of administration: subcutaneous, anatomical site: left arm, batch number: M035696 and expiry date: 07-Nov-2017). On the same day about 5 minutes after vaccination, the patient developed a 2-inch red rash at the vaccination site. By evening, the rash spread 6-8 inches. On an unknown date in May-2017, the rash became red, swollen and developed into a welt. Additionally, the patient had muscle aches for few days. It was reported that, laboratory tests were not performed, and the patient did not receive any medication. On 23-May-2017, within 10 days of vaccination, the patient had recovered from the vaccination site rash, vaccination site urticaria, vaccination site swelling and vaccination site erythema. At the time of this report, the patient had recovered from all the events (myalgia, rash erythematous, urticaria, vaccination site reaction and vaccination site swelling). The causal relationship between all the events with FLUVIRIN and ZOSTAVAX was not reported. The reporter assessed this case as non-serious. Update on 18-Jun-2018: Non-significant case correction was performed with IRD 19-May-2018: The word 'serious' from the lead sentence was deleted. Update on 11-Jul-2018: Non-significant case correction was performed with IRD 19-May-2018: The sentence was corrected from 'vaccination site reaction about 5 min of vaccine administration' to 'vaccination site reaction about 5 min after vaccine administration' and added sentence 'the co-suspect is ZOSTAVAX vaccine, administered on the same day ' in the case comment. Upon internal review it was realized that, the reporter type, verbatims for the events (muscle ache, rash erythematous, welt and vaccination site swelling) and onset latency for the event (rash erythematous) was incorrect. Hence the reporter type was changed from pharmacist to other health professional in the general tab. The event verbatims was rephrased from 'In addition, the patient continued to have muscle aches for the a few days' to 'muscle aches' for the event muscle aches, for the event rash erythematous from [On the same date, about 5 minutes after vaccine administration, the patient] developed a 2 inch red rash at the site of vaccination. Then, in the evening, the rash spread 6 to 8 inches. [On an unknown date in May,] the rash became red, [swollen and to '2 inch red rash at the site of vaccination/Rash spread 6 to 8 inches' for the event welt from '[On an unknown date in May, the rash became red, swollen and] formed into a welt' to 'rash became [red, swollen] and formed into a welt' and for the event vaccination site swelling from '(On an unknown date in May, the rash became red,] swollen [and formed into a welt'] to 'rash became [Red], swollen [and formed into a welt]'. The narrative was amended accordingly. On 13-Jul-2018: Case was opened in error.